Sanofi Trades In Phase III TroVax For Early-Stage Ophthalmology Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi Aventis returns cancer vaccine TroVax to Oxford BioMedica and signs option deal for four gene-based ocular products.